• Read more about Jeff’s Weight Loss Surgery Success Story

When Jeff's weight started to impact his performances and his health, he turned to Cooper and a team who could help him succeed. Not only was Jeff’s weight affecting his performance, he was beginning to develop serious chronic illnesses

• Read more about MDA 2016-0046 Exceptional Responders

Short Title: Exceptional Responders

This clinical trial studies eliminating surgery and how well radiation therapy after systemic therapy works in treating patients with HER2 positive or triple negative breast cancer when image-guided biopsy shows no residual cancer. Patients then receive standard breast radiotherapy.

Study Number:

2016-0046

Study Status:

Enrolling

Treatment Agent:

Radiation, Surgery

Resources and Links

National Clinical Trial Identified Number: NCT02945579

Disease:

• Breast Cancer,
• Estrogen Receptor Negative,
• HER2 Positive Breast Carcinoma,
• HER2/Neu Negative,
• Invasive Breast Carcinoma,
• Progesterone Receptor Negative,
• Triple-Negative Breast Carcinoma,
• Stage 1A, 1B, II, IIA, IIB

Study Phase:

Not applicable

researchcancer@cooperhealth.edu

Hide from Search:

Off

Physician Name:

• Catherine E. Loveland-Jones, MD, MS, FACS

• Read more about WO43919-INAVO121

Short Title: WO43919 - INAVO121

This is a Phase III, multicenter, randomized, open-label, global study designed to evaluate the efficacy and safety of inavolisib plus fulvestrant compared with alpelisib plus fulvestrant in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) -negative, PIK3CA-mutated, locally advanced (LA) or metastatic breast cancer (mBC), who progressed during or after cyclin dependent kinase 4/6i (CDK4/6i)-based therapy.

Study Number:

WO43919-INAVO121

Study Status:

Enrolling

Treatment Agent:

Inavolisib, Fulvestrant, Alpelisib

Resources and Links

National Clinical Trial Identified Number: NCT05646862

Disease:

• Breast

Study Phase:

III

researchcancer@cooperhealth.edu

Hide from Search:

Off

Physician Name:

• Kamel Abou Hussein, MD

Department:

• Hematology and Medical Oncology

• Read more about EVoPAR -Prostate 01

Short Title: EVoPAR -Prostate 01  

The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.

Study Number:

AZD5305 - D9723C00001

Study Status:

Enrolling

Treatment Agent:

Saruparib, Abiraterone Acetate, Darolutamide, Enzalutamide

Resources and Links

National Clinical Trial Identified Number: NCT06120491

Disease:

• Metastatic Castration-Sensitive Prostate Cancer,
• Prostate Cancer

Study Phase:

III

researchcancer@cooperhealth.edu

Index Extra:

prostate

Hide from Search:

Off

Physician Name:

• Christian Squillante, MD

Department:

• Hematology and Medical Oncology

• Read more about CompassHER2

Short Title: CompassHER2

This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.

Study Number:

A011801

Study Status:

Enrolling

Treatment Agent:

Trastuzumab emtansine, Tucatinib

Resources and Links

National Clinical Trial Identified Number: NCT04457596

Disease:

• HER2 Positive Breast Carcinoma,
• Invasive Breast Carcinoma,
• Multifocal Breast Carcinoma,
• Synchronous Bilateral Breast Carcinoma

Study Phase:

III

ResearchCancer@CooperHealth.edu

Hide from Search:

Off

Physician Name:

• Rebecca J. Jaslow, MD

Department:

• Breast Cancer

• Read more about DIRECT

Short Title: DIRECT

This phase II trial tests how well an imaging procedure called fludeoxyglucose F-18 (FDG) positron emission tomography/computed tomography (PET/CT) works in predicting response to standard of care chemotherapy prior to surgery in patients with HER2-positive stage IIa-IIIc breast cancer. FDG is a radioactive tracer that is given in a vein before PET/CT imaging and helps to identify areas of active cancer. PET and CT are imaging techniques that make detailed, computerized pictures of areas inside the body. The use of FDG-PET/CT may help doctors better decide if a patient needs more or less treatment before surgery in order to get the best response. This study evaluates whether FDG-PET/CT is useful in predicting a patient's response to standard of care chemotherapy.

Study Number:

EA1211

Study Status:

Enrolling

Treatment Agent:

Chemotherapy

Resources and Links

National Clinical Trial Identified Number: NCT05710328

Disease:

• HER2-Positive Breast Carcinoma,
• Invasive Breast Carcinoma

Study Phase:

II

researchcancer@cooperhealth.edu

Hide from Search:

Off

Physician Name:

• Kamel Abou Hussein, MD

Department:

• Breast Cancer

• Read more about TROPION Breast04

Short Title: TROPION Breast04

This is a Phase III, 2-arm, randomised, open-label, multicentre, global study assessing the efficacy and safety of neoadjuvant Dato-DXd plus durvalumab followed by adjuvant durvalumab with or without chemotherapy compared with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab with or without chemotherapy in participants with previously untreated TNBC or hormone receptor-low/HER2-negative breast cancer.

Study Number:

D926QC00001

Study Status:

Enrolling

Treatment Agent:

Dato-DXd, Durvalumab, Pembrolizumab, Doxorubicin, Epirubicin, Cyclophosphamide, Paclitaxel, Carboplatin, Capecitabine, Olaparib

Resources and Links

National Clinical Trial Identified Number: NCT06112379

Disease:

• Breast Cancer

Study Phase:

III

researchcancer@cooperhealth.edu

Hide from Search:

Off

Physician Name:

• Kamel Abou Hussein, MD

Department:

• Breast Cancer,
• Hematology and Medical Oncology

• Read more about BR009

Short Title: OFSET

To determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).

Study Number:

BR009

Study Status:

Enrolling

Treatment Agent:

Ovarian Function Suppression, Aromatase Inhibitor, Adjuvant Chemotherapy, Ovarian Function Suppression

Resources and Links

National Clinical Trial Identified Number: NCT05879926

Disease:

• Breast Cancer

Study Phase:

III

ResearchCancer@CooperHealth.edu

Hide from Search:

Off

Physician Name:

• Danny Markabawi, MD

Department:

• Hematology and Medical Oncology

• Read more about LU008

Short Title: LU008

This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to standard treatment (image guided radiation therapy [IGRT] and chemotherapy followed by immunotherapy with durvalumab) versus standard treatment alone in treating patients with non-small cell lung cancer that cannot be treated by surgery (inoperable). SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. IGRT is a type of radiation that uses a computer to create picture of the tumor, to help guide the radiation beam during therapy, making it more accurate and causing less damage to healthy tissue.

Study Number:

LU008

Study Status:

Enrolling

Treatment Agent:

Cisplatin, Carboplatin, Paclitaxel, Pemetrexed, and Etoposide

Resources and Links

National Clinical Trial Identified Number: NCT05624996

Disease:

• Locally Advanced Lung Non-Small Cell Carcinoma,
• Stage IIB Lung Cancer AJCC v8,
• Stage III Lung Cancer AJCC v8

Study Phase:

III

ResearchCancer@CooperHealth.edu

Hide from Search:

Off

Physician Name:

• Joseph F. Lombardo, DO, PharmD

Department:

• Radiation Therapy,
• Lung Cancer

• Read more about MajesTEC-9

Short Title: MajesTEC-9

Multiple myeloma is an incurable, malignant, plasma cell disorder. Teclistamab (JNJ-64007957) is a full-size, Immunoglobulin G (IgG) 4 proline, alanine, and alanine (PAA) bispecific antibody that targets the cluster of differentiation (CD3) receptor expressed on the surface of T cells and B cell maturation antigen (BCMA). With its dual binding sites, teclistamab is able to draw CD3 positive T cells in close proximity to BCMA positive cells, resulting in T-cell activation and subsequent lysis of BCMA positive cells. Pomalidomide is a third-generation immunomodulatory imide drug (IMiD) that exerts potent, direct tumoricidal and immune-enhancing effects and Carfilzomib is a second-generation proteasome inhibitor that inhibits proteasome which results in disruption of protein turnover and induces apoptosis.

Study Number:

MajesTEC-9

Study Status:

Enrolling

Treatment Agent:

Teclistamab, Pomalidomide, Bortezomib, Dexamethasone, Carfilzomib

Resources and Links

National Clinical Trial Identified Number: NCT05572515

Disease:

• Relapsed or Refractory Multiple Myeloma

Study Phase:

III

ResearchCancer@cooperhealth.edu

Hide from Search:

Off

Physician Name:

• Tulin Budak-Alpdogan, MD

Department:

• Hematology and Medical Oncology